Effect of BioDMARDs on Diabetes risk in 6400+ Psoriasis pts IL-23i and IL-17Ai associated w/ -lower risks of diabetes https://pbs.twimg.com/profile_images/1800478984926334976/yyyPLP4A_normal.jpg […]

Avacopan in the real world: we need to be braver If we want to get steroid-sparing benefit in AAV, we

Can the blood reflect what’s happening in the joint? In early RA, 11 synovial proteins mirrored serum levels, forming https://pbs.twimg.com/profile_images/1525262133575012354/Lfut18gD_normal.jpg

A systematic review by Dr. SRamiro et al evaluated efficacy of b/tsDMARDs on peripheral axSpA Majority on bDMARDs (TNFi https://pbs.twimg.com/profile_images/1027501556868870145/2culK0bN_normal.jpg

Cool study using vasculitis patient-powered reserach network (VPPRN) “SNOT-22” tool captures sinonasal symptoms; associ https://pbs.twimg.com/profile_images/1982460526815764480/EQEuBdmh_normal.jpg john+RNV2@john… Sun, 10/26/2025 – 12:54

Miller et al. Fibrinogen for GCA diagnosis and flare identification. Similar to ESR/CRP in diagnosis. For flares, lower https://pbs.twimg.com/profile_images/1389468430160510976/sooz0Ud3_normal.jpg john+RNV2@john…

ASAS recommends standardised reporting for 20 key outcomes in axSpA trials, 10 for all studies, 10 specific to DMARD tri

Poster evaluating representation in trials of AAV and GCA Results mirror those observed in other fields; need to keep a

#ACR25 Abstr#776 2-Year SELECT-GCA RCT showed that #GCA patients receiving continuous UPA15 to 2-yr maintained their rem https://pbs.twimg.com/profile_images/1625445768768135171/M24lCgC__normal.jpg john+RNV2@john… Sun,

Fascinating: tDR-1, a microbial sRNA, appears protective for RA in at risk ACPA+ pts: – tDR-1 higher = less develop

No seasonal pattern in GCA! We have also looked at this in our data and similarly found no trends It

Rheumatoid arthritis and the ‘big bang’ at the ACR! Janet.Pope@sjh… Sun, 10/26/2025 – 12:15

#0191 We found that in a large South London RA cohort, use of advanced therapy in moderate disease (DAS28 3.2-5.1)

Real-world T2T strategy from MONITOR-PsA cohort: 🎯 At 48 weeks – 33.6% (49/146) of pts achieved PASDAS ‘moderate’ res https://pbs.twimg.com/profile_images/1027501556868870145/2culK0bN_normal.jpg

Albach et al. CAR T-cells in D2T RA. 6 patients. Safety looks ok. ACR20 in 4/6, ACR50 in 2/6. ACPA

SELECT-GCA (upadacitinib in GCA for 52w) we hoped it might have ongoing effect post-cessation Do we need to continue up

#0776 In the 2-yr SELECT-GCA trial, continued upadacitinib 15mg maintained remission in 69% vs 29% who switched to PBO, https://pbs.twimg.com/profile_images/1489576716322447363/HmrVJtAH_normal.jpg

RheumNow’s expanded coverage of the #ACR2025 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. A https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john…

Singla et al. In secukinumab phase 3 trials, fungal (inc candida) infections uncommon. 5.51 for sec vs 3.39 for PBO

Schmidt et al. 2 year results of SELECT-GCA, upadacitinib in GCA. Remission 69% if upa continued vs 29% if stopped.

Not all inflammatory nasal lesions are vasculitis! Dr. Zacharek presents from the ENT perspective @RheumNow #ACR25 http https://pbs.twimg.com/profile_images/1684945388665442304/yPWpfGoX_normal.jpg john+RNV2@john… Sun,